IL10 and myeloid sarcoma: Another study revealed a significant decrease of IFN-γ and an increase of IL-4, IL-5, and IL-10 in the supernatants of GA-stimulated (20 μg/ml) PBMCs of GA-treated MS patients in the first year of treatment [38].